Zoetis Inc. (ZTS)

Zoetis is the world's largest pure-play animal health company — the first and most obvious analogy to a human pharmaceutical giant, but focused exclusively on veterinary medicine. Spun out of Pfizer in 2013, it discovers, develops, manufactures, and commercializes medicines, vaccines, diagnostic products, biodevices, genetic tests, and precision health solutions for both companion animals (dogs, cats, horses) and livestock (cattle, swine, poultry, fish, sheep). Its customers are veterinarians, livestock producers, and increasingly — through direct-to-consumer marketing programs — pet owners themselves. Distribution runs through veterinary clinics, farm-supply channels, and a growing e-commerce presence.

The business solves a fundamental problem: animals get sick, owners and farmers want them healthy, and specialized veterinary pharmaceuticals are meaningfully harder to develop than their human equivalents due to species-specific biology, regulatory complexity across markets, and the economic incentives of farming industries.

Revenue quality is high but not subscription-pure. The majority of revenue is quasi-recurring — pets require ongoing parasite prevention, allergy medication (Apoquel is taken daily), and vaccines on annual cycles. The livestock side is more seasonal and transactional, tied to herd health protocols. There are no long-term contracts in the traditional sense, but veterinarian loyalty, regulatory moats, and product switching costs create extremely durable revenue streams. The Petcare Rewards program (2.5 million enrolled members by 2023) is an increasingly important direct channel.

Pricing power has historically been strong — Zoetis raised prices on key products 5–10% annually for much of the 2018–2024 period with little volume loss, reflecting the "humanization of pets" megatrend. The Q1 2026 crack is the first meaningful evidence that pricing power may be more elastic than assumed, particularly among younger, more financially stretched pet-owner demographics.

Geographic concentration risk is moderate. The U.S. represents roughly 52% of revenues — significant but not extreme. No single customer exceeds 10% of revenue. The top ten product lines account for about 49% of sales, creating moderate product concentration (Apoquel and Cytopoint alone are likely $1.5B+ annually).

Total annual revenue for 2025 was $9.47 billion, up from $6.7B in 2020 — a 5-year CAGR of approximately 7.2%. The company employs roughly 14,000–15,000 people globally.

Profitability is best-in-class for the sector. A 71.8% gross margin reflects the premium pharmaceutical nature of the business — comparable to human specialty pharma, not generic drug makers. Adjusted EBIT margins have held remarkably stable at 36–38% across market cycles, demonstrating genuine operating leverage and pricing discipline.

Cash flow quality is excellent. Operating cash flow consistently exceeds reported net income (a healthy sign), and FCF conversion has been strong at 80–90% of adjusted net income. The improvement in FCF from ~$1.3B in 2022 to $2.3B in 2024 reflects both earnings growth and capex normalization post-ERP investment. At the current price of $75.48 with ~$2.28B in annual FCF, the FCF yield is approximately 7.3% — a meaningfully cheap entry for a wide-moat compounder if the current headwinds prove cyclical rather than structural.

Balance sheet carries meaningful but manageable leverage. As of fiscal year 2025, Zoetis held approximately $9.0B in long-term debt against $2.3B in cash, implying net debt of roughly $6.7B. Against ~$4.0B in EBITDA, the net debt/EBITDA ratio is approximately 1.7× — elevated but not distressing. Debt maturities are staggered across years; no imminent refinancing cliff. The debt-to-equity ratio is 2.71×, driven by aggressive capital return rather than financial stress. Off-balance-sheet liabilities include operating leases and pension obligations that are not material relative to earnings power.

Capital intensity is moderate. Maintenance capex runs roughly $250–$350M annually, with total capex including the multi-year ERP transformation higher (around $500–700M). The ERP investment is a temporary drag that should normalize by 2027. Working capital dynamics are favorable: Zoetis collects cash within standard commercial terms, and the business doesn't require long advance funding of customer operations.

Return on invested capital (ROIC) is estimated at 18–22% over the past five years — well above the company's weighted average cost of capital (~8–9%). Return on equity is exceptionally high at 80%+ due to the leveraged balance sheet structure. These are the fingerprints of a genuine moat business generating economic surplus.

CEO: Kristin C. Peck — appointed January 2020; tenure of 6+ years. Peck is a career operator and strategist, not a financier. Before becoming CEO, she was EVP and Group President of U.S. Operations, Business Development and Strategy at Zoetis, and before that served as EVP of Worldwide Business Development and Innovation at Pfizer — a member of Pfizer's Executive Leadership Team. Earlier career included Boston Consulting Group, private equity, and J.P. Morgan real estate finance. She holds an MBA from Columbia Business School. Critically, she helped shepherd Zoetis through its 2013 IPO, giving her deep institutional knowledge of the company's history, culture, and strategy. This is an operator who has grown up with the company, not a hired-gun restructurer.

Track record under Peck is solid, not flawless. Revenue grew from ~$6.7B (2020) to $9.47B (2025), a CAGR of 7.2%. Adjusted EPS grew from roughly $3.50 (2020) to ~$6.35 (2025), compounding at approximately 12% annually. She successfully launched Librela (the osteoarthritis therapy for dogs), expanded internationally, and pivoted the company toward diagnostics and biologics. The stock reached an all-time high near $250 in late 2021. The Q1 2026 guidance cut is the most significant stumble of her tenure — and it came from a competitor and macro-driven headwind rather than an internal execution failure. Importantly, she responded quickly by launching a comprehensive cost and productivity program.

Skin in the game is modest. Peck directly owns approximately 0.025% of the company's shares — worth roughly $8–9M at current prices (materially more before the decline). Total annual compensation of approximately $19M (93% equity-linked) creates strong alignment on stock price. An Intent to Sell notice was filed in February 2026 for 20,000 shares — noted, but routine for executives managing tax and diversification. Separately, Director Michael McCallister made a notable open-market purchase recently, which is a more constructive signal.

CFO: Wetteny Joseph — a finance executive with deep Zoetis institutional knowledge, having been with the company through its growth era. He has communicated clearly and credibly to institutional investors, including noting at the Bank of America Animal Health Summit in February 2026 that management sees "a disconnect between that and where we're valued today" — an unusually candid acknowledgment that the stock is cheap.

Board quality is reasonable. The Chairman and CEO roles are separate. Directors include experienced executives from pharmaceutical, consumer, and financial backgrounds. Tenure of ~11.6 years for the board reflects institutional continuity. No major activist has disclosed a stake publicly.

Capital allocation philosophy is balanced: Zoetis has consistently grown its dividend (13% increase in 2025 to $2.03/share), pursued accretive bolt-on acquisitions (Veterinary Pathology Group in the UK, the pending Neogen genomics acquisition), divested non-core assets (the Medicated Feed Additives portfolio sold to Phibro for $350M), and repurchased shares using convertible debt funding — a financially sophisticated approach that added 3% to adjusted EPS in Q1 2026 alone. The MFA divestiture is particularly compelling as a focus-sharpening move.

The moat is real, wide, and multi-layered — but currently under stress at the edges. Zoetis's competitive advantages operate simultaneously across four distinct dimensions:

1. Intangible Assets (Patents & Regulatory Approvals). Zoetis holds 5,000+ granted patents. Developing a veterinary pharmaceutical from scratch requires navigating species-specific biology, multi-jurisdictional regulatory approvals (FDA-CVM in the U.S., EMA in Europe, plus country-by-country elsewhere), and extensive clinical trials. This process takes 7–12 years and hundreds of millions of dollars. The regulatory hurdles create enormous barriers to generic entry, though they don't prevent it entirely once patents expire — as the current Apoquel generic competition demonstrates. The monoclonal antibody platform (Cytopoint, Librela, Solensia) enjoys its own protection because biologics are harder to generic-ize than small-molecule drugs.

2. Switching Costs & Veterinarian Relationships. Zoetis has approximately 4,000+ sales representatives globally who maintain persistent, relationship-based selling to veterinary clinics. Veterinarians are conservative prescribers — they adopt a trusted product and stick with it unless a generically equivalent alternative is available. The deep embedding of Zoetis products in veterinary protocols creates significant inertia. The launch of bundled diagnostic-and-treatment offerings deepens these relationships further.

3. Scale Economics. With 27 global manufacturing sites and the highest R&D spend in the animal health industry (over $650M annually — well above all competitors), Zoetis can absorb fixed costs across a $9.5B revenue base that no competitor can match. Elanco's revenue base is roughly half; Merck Animal Health is a division of a larger company. This creates a self-reinforcing cycle: scale enables more R&D, which enables more products, which enables more scale.

4. First-Mover Category Creation. Apoquel (canine itch) and Cytopoint (biologic canine dermatology) created entirely new treatment categories that didn't exist before. Librela and Solensia did the same for osteoarthritis pain in pets. When you create a category, you own it for years — competitors are always behind by the time they arrive.

Moat trend: Stable to narrowing at the edges, but not broken. The core biologics platform (Cytopoint, Librela, Solensia, and 12+ pipeline candidates) remains years ahead of competitors. The pipeline, not the legacy franchise, is the key moat renewal mechanism. Zoetis has done this before — Apoquel and Cytopoint replaced earlier products; the next generation will replace them. The question is the timing and cost of the transition.

Disruption risk from AI: Animal health data analytics and predictive diagnostics will evolve, but the core drug development and regulatory moat is extremely hard to replicate digitally. AI may accelerate drug discovery timelines, which benefits Zoetis (with its scale R&D) more than smaller competitors.

The global animal health market is a genuine secular growth story. The market was valued at approximately $68–73B globally in 2025 and is projected to grow at a CAGR of 9–11% through 2033–2034, reaching $150B+. The U.S. companion animal market alone, valued at ~$8B in 2024, is forecast to grow at nearly 10% CAGR through 2030. These are not fringe estimates — they reflect durable structural drivers.

Secular tailwinds are structural and durable:

The "humanization of pets" — treating pets as family members, not property — is driving expanded willingness-to-pay for veterinary care across developed markets. Approximately 66% of U.S. households owned a pet as of 2024, totaling 86.9 million homes. Global protein demand (driving livestock health investment) continues to grow. Rising pet insurance penetration in the U.S. and Europe lowers price sensitivity for expensive treatments. The shift from reactive (treat when sick) to preventive and precision care expands the addressable market per animal. These tailwinds are multi-decade, not cyclical.

The current headwind is real but likely cyclical. The Q1 2026 data shows that Gen Z and millennial pet owners — disproportionately hit by inflation, student debt, and housing costs — are cutting back on discretionary veterinary visits and premium treatments. This is a K-shaped economic phenomenon: affluent pet owners continue spending; budget-constrained younger households pull back. Historically, pet spending has proven highly resilient through recessions (it held up better than most consumer categories in 2008–2009 and recovered rapidly in 2020), but the current environment is unusual in its concentration of pressure on a specific demographic cohort.

Competitive intensity is rising. The animal health market has 4–5 serious global competitors:

Regulatory environment is a net moat, not a risk. Heavy species-specific regulatory requirements (FDA-CVM, EMA) protect incumbents from fast-follower entry. Antibiotic restrictions in livestock create innovation demand in vaccines and alternatives — Zoetis is well-positioned here through its biologics platform. However, potential regulatory actions on specific products (Librela faced safety scrutiny in some markets for neurological side effects) are an ongoing monitoring requirement.

Cyclicality: In 2008–2009, animal health spending proved resilient relative to discretionary consumer spending. In 2020, the industry boomed as pandemic pet adoption drove unprecedented demand. The 2026 experience is the first episode of genuine demand softness in the sector in over a decade, creating temporary overhang on investor sentiment.

At $75.48, Zoetis is trading at valuation levels that have not been seen since its early years as an independent public company. The stock sat at $172 just one year ago; the 52-week high was $172.23. The decline is −56% from the high — a collapse typically associated with businesses in terminal decline, not the world's leading animal health company with 71% gross margins and $2.3B in annual free cash flow.

Owner Earnings Calculation: Adj. Net Income ~$2.91B midpoint guidance + D&A ~$750M − Maintenance Capex ~$350M = Owner Earnings ~$3.31B. At the current market cap of $31.2B, the price/owner earnings multiple is approximately 9.4× — a level at which high-quality businesses rarely trade for extended periods without being taken private or rebounding.

DCF Sanity Check (conservative): Assume 2026 revenue of $9.82B (midpoint guidance); 3% revenue growth for 3 years, then 5% thereafter; EBITDA margins flat at 42%; terminal growth of 3.5%; discount rate 10%. This produces an intrinsic value estimate of approximately $95–$110 per share. At $75, the stock is trading at roughly a 20–30% discount to even a conservative DCF — which assumes no improvement in the current operating environment.

Why is the stock at $75? Three compounding negatives hit simultaneously: (1) a rare Q1 2026 miss on both revenue AND EPS, breaking a long streak of beats; (2) a significant full-year guidance cut that forced analysts to reset models; (3) the revelation that pet owner price sensitivity may be structural, not purely cyclical — threatening the "humanization of pets" premium thesis. The stock was already declining from its 2021 peak as Librela disappointed U.S. launch expectations and interest rates reset growth stock valuations. The Q1 2026 report was the breaking point: the stock dropped approximately 20% in a single day, its largest single-day decline as a public company.

Margin of Safety: At $75, the stock trades at what appears to be 2014–2015 prices for a dramatically larger and more profitable company. Even in a scenario where growth is permanently impaired at 3% annually and margins contract 200 basis points, the intrinsic value is approximately $80–$85. That implies limited downside from fundamentals alone, with the real bear case being a multiple compression to near-distress levels (8–9× earnings) if sentiment continues to deteriorate.

Dividends: Zoetis paid $2.03/share in dividends for 2025, representing a 13% year-over-year increase. At the current price of $75.48, the dividend yield is approximately 2.85% — more than triple the historical yield, and a genuine income floor for patient investors. The FCF payout ratio is approximately 38% ($860M dividends / ~$2.28B FCF), leaving substantial room for continued growth and is unlikely to be cut.

Share Buybacks: Management has been executing convertible-debt-funded buybacks — a financially sophisticated structure that reduced adjusted share count meaningfully and contributed 3% to EPS growth in Q1 2026. Share count has declined from ~480M shares in 2020 to approximately 424M by Q1 2026. This represents genuine value accretion through capital return. Stock-based compensation dilution exists but is modest relative to the buyback program.

M&A Track Record — mixed but generally disciplined: Key recent moves include (a) the acquisition of Veterinary Pathology Group in the UK to expand diagnostics, consistent with the strategy of deepening veterinary relationships; (b) the pending acquisition of Neogen's animal genomics business, expected to close in H2 2026, which expands Zoetis into genetic testing — a logical adjacency; (c) the divestiture of the Medicated Feed Additives portfolio to Phibro for $350M in 2024, a smart pruning of a low-margin, commoditizing business that sharpened focus. These are disciplined bolt-ons, not empire-building overreach. Zoetis notably did not make any mega-deal acquisitions during the low-rate era (unlike many peers who overpaid).

R&D Reinvestment: R&D spend exceeds $650M annually, the highest in the animal health industry. This is the most important capital allocation decision the company makes — and it is being directed toward the 12 pipeline blockbuster candidates in high-value therapeutic areas (CKD, oncology, cardiology, anxiety, obesity) that represent $5B+ in TAM opportunity.

Debt Reduction: The priority in 2026 appears to be maintaining the dividend, funding the Neogen acquisition, and executing the cost program — debt reduction is not an explicit near-term priority. The maturity schedule appears manageable, and interest coverage remains comfortable given $4B in EBITDA against interest expense of approximately $250–300M.

The strategic response to Q1 2026 was swift and multi-pronged. Management immediately launched a "comprehensive cost and productivity program" — tightening discretionary spending, driving procurement efficiencies, and "assessing organizational levers." The language suggests potential restructuring or headcount rationalization is on the table, though specifics were not disclosed in Q1. This is a management team that takes action, not one that waits.

Pipeline advancement is the core long-term strategy. The 12 potential blockbuster candidates are in advanced stages, with near-term catalysts including: (1) Cytopoint long-acting — regulatory approval expected late 2026, which would extend treatment intervals and reduce administration burden, potentially reigniting dermatology growth; (2) Lenivia — launched in EU and Canada in H1 2026, a next-generation OA pain therapy; (3) Portela — already approved, a novel companion animal product; (4) pipeline candidates targeting CKD, oncology, and cardiology — entirely new categories where Zoetis has no current revenue but significant unmet need. Management has stated the company is "on track to receive a significant approval in a major market every year for the next several years."

Commercial execution is being sharpened. The diagnosis in Q1 was that a portion of the U.S. companion animal decline was a market problem (fewer vet visits, price sensitivity) but another portion was self-inflicted market share loss. Management is redeploying sales resources and refining promotional strategies to recapture share, particularly in dermatology where Apoquel's generic competition is most acute.

Diagnostics expansion continues — the Neogen genomics acquisition and VPG acquisition deepen the diagnostics footprint, which is strategically important because diagnostics drive treatment protocols and create an ecosystem of product referrals. The Vetscan point-of-care platform is a growing recurring revenue stream.

Fiscal year alignment (shifting to a calendar-year fiscal year) was completed in 2025 and will create cleaner year-over-year comparisons going forward, removing a structural source of investor confusion.

Guidance credibility: Zoetis had an unusually strong beat record before Q1 2026 (beating EPS in 3 of the prior 4 quarters by 4–9%). The Q1 2026 miss and guidance cut will set a lower bar for the balance of 2026. Management's revised guidance ($9.68–$9.96B revenue; EPS $6.85–$7.00) already embeds the challenging environment, creating a meaningful probability that the company surprises positively in H2 2026 if conditions stabilize.

AI is primarily a tool, not a threat, for Zoetis. The core business — developing novel pharmaceutical and biologic compounds for veterinary use — is not disruptable by AI in any near-term sense. Regulatory approval requirements, manufacturing scale, and veterinarian relationships are physical, regulatory, and relational advantages that AI cannot replicate. AI could, however, compress drug discovery timelines and improve target identification — which, if anything, benefits Zoetis's scaled R&D engine more than smaller competitors who lack the compute and data infrastructure to match it.

Internal AI deployment: Zoetis has been investing in digital health and data-driven precision animal health tools — including AI-powered diagnostic assistance, predictive health analytics for livestock herds (integrating with wearable sensors and herd management systems), and data analytics embedded in the Vetscan diagnostic platform. The multi-year ERP transformation underway creates the data infrastructure necessary for more sophisticated AI applications. The 2025 R&D roadmap features over 130 innovation programs, some of which incorporate AI/ML for target identification and clinical trial design.

AI as revenue opportunity: The most exciting near-term AI-adjacent opportunity is in precision livestock health — using sensor data, genomic information (hence the Neogen acquisition), and predictive analytics to help farmers optimize herd health outcomes. This is a data monetization opportunity that Zoetis is uniquely positioned to develop given its scale across 45 countries and multiple species. Estimated TAM for digital livestock management is still nascent but growing rapidly.

R&D spend as % of revenue: Approximately 7–8% of revenue is invested in R&D ($650M+), the highest absolute and percentage figure in the animal health industry. This is the primary technology investment, and it is product-development focused rather than pure basic research. Zoetis is a technology leader in veterinary biologics and diagnostics; it is a follower in enterprise software and data infrastructure, though the ERP investment is closing that gap.

Proprietary data assets: The Vetscan diagnostic network, the Petcare Rewards program (2.5M enrolled consumers), genomic data from the Neogen acquisition, and clinical trial databases accumulated over 75 years of veterinary R&D represent substantial proprietary data that becomes more valuable in an AI world. This data moat is underappreciated and undermonetized today.

Insider ownership is low but not alarming for a large-cap spinoff. CEO Kristin Peck owns approximately 0.025% of shares — roughly $8–9M at current prices. Total insider ownership is a small fraction of the float, consistent with a professional management team at a large public company rather than a founder-led business. The February 2026 Intent to Sell notice (20K shares by CEO) was filed before the stock's major decline, and the sale price would have been around $127/share — still a painful loss relative to today's levels, but routine tax management for an executive with vested equity. More encouraging: Director Michael McCallister made an open-market purchase following the Q1 2026 decline — a genuine conviction signal.

Major institutional holders include Vanguard, BlackRock, State Street (passive index exposure), and fundamental long-only investors including T. Rowe Price, Wellington, and Fidelity. These are predominantly long-duration fundamental investors, not fast-money traders. The concentration of long-term holders creates stability in the register, though it also means that if these investors lose conviction on the multi-year thesis, the selling pressure can be sustained. Institutional ownership trends post-Q1 2026 should be closely monitored in 13-F filings for Q2 2026.

Short interest: With the stock down 56% from its highs, short interest has likely increased materially — but the stock at $75 may also be attracting short-covering activity from bears who have already captured their gains. An elevated short interest (above 5% of float) would represent a contrarian signal and potential catalyst for a short squeeze on positive news. Current short interest data should be verified through current filings, but the conditions for a technical squeeze are improving as the stock bottoms.

Analyst consensus: Post the Q1 2026 miss, the analyst community has bifurcated. The consensus rating from multiple aggregators shows "Moderate Buy" to "Buy" — approximately 9 buy ratings, 1 moderate buy, and 8 holds, with 0 sell ratings. Price targets range from $99 (UBS Neutral, post-Q1 cut) to $190+ (Barclays pre-Q1). The post-Q1 consensus has converged around $136–$147 — representing 80–95% upside from current levels even from analysts who just cut their targets. The enormous disconnect between consensus targets and current price reflects both the scale of the recent decline and analysts' reluctance to downgrade further given the valuation level.

No activist involvement has been publicly disclosed. However, at a $31B market cap with $9.5B in revenue and $2.3B in FCF — and a stock down 56% — the company is not immune to activist approaches, particularly focused on capital structure optimization or accelerating cost actions.

• 01
  Structural Erosion of U.S. Premium Companion Animal Market

  The most serious risk is that the Q1 2026 decline is not cyclical but represents a permanent K-shaped bifurcation in pet healthcare spending. If Gen Z and millennial pet owners permanently downgrade their veterinary care patterns — shifting from specialty treatments to generic alternatives — Zoetis's premium pricing model for dermatology and OA pain products could face sustained headwinds. The "humanization of pets" thesis assumed relatively inelastic demand; Q1 2026 showed it is more elastic than believed at premium price points. A structural impairment of 15–20% of U.S. companion animal revenue would be worth ~$4–5/share in earnings power. Bear-case assumption: U.S. companion animal revenue declines 5% annually for 3 years before stabilizing.

• 02
  Intensifying Multi-Front Generic and Competitive Pressure

  For the first time, Zoetis faces simultaneous competition in dermatology (Elanco's Zenrelia vs. Apoquel; Merck's Numelvi), parasiticides (Credelio Quattro), and OA pain (multiple entrants targeting Librela's category). If Zoetis loses significant market share in 2–3 high-value categories at once before the pipeline blockbusters generate revenue, the earnings shortfall could be more severe and prolonged than current guidance implies. Generic erosion of Apoquel — a product that contributed $600M+ annually — is real and ongoing. Bear-case assumption: Dermatology revenues decline 25% over 3 years from competition + generics.

• 03
  Balance Sheet Vulnerability in a Credit Crunch

  At $9.0B in long-term debt against declining revenue and earnings, if the operating environment deteriorates sharply (severe U.S. recession, sustained vet visit decline), the net debt/EBITDA ratio could climb above 2.5–3×, potentially triggering covenant concerns or forcing a dilutive equity raise. This is not the base case — FCF coverage remains robust — but it is not a zero-probability outcome if both revenue and margins compress simultaneously. The dividend (~$860M/year) consumes a significant portion of FCF under stress scenarios. Bear-case assumption: Net debt/EBITDA reaches 2.5× by 2027 if guidance misses by 10%+.

• 04
  Pipeline Execution Risk

  The bull case depends heavily on the 12 pipeline blockbusters delivering on schedule and at scale. Clinical failures, regulatory delays, or post-launch disappoints (Librela U.S. was a cautionary tale) would extend the revenue trough. The pipeline covers entirely new therapeutic categories (CKD, oncology, cardiology for pets) — categories that don't yet have established demand or reimbursement pathways. Convincing vets and pet owners to spend on novel treatments for chronic conditions is harder than selling a daily allergy pill. Risk: 2–3 pipeline candidates fail or launch below expectations, delaying recovery by 2–3 years.

• 05
  Macro, FX, and Tariff Headwinds

  50% of Zoetis revenue is international — a significant exposure to U.S. dollar strength. FX was a 2% headwind to reported revenue in recent quarters. Additionally, tariff uncertainty (which caused a mid-2025 guidance update) creates ongoing manufacturing cost risk for a company with 27 global production sites and significant cross-border material flows. A sustained strong dollar or new tariff regimes could reduce reported earnings by $0.30–$0.50/share annually. China, which represents 4–5% of revenue, carries specific geopolitical risk. Bear-case: Dollar strengthens 10%+ and tariff headwinds add $200M+ to costs.

Base Case: U.S. companion animal business stabilizes in H2 2026 (not recovers — stabilizes) as the lowest-hanging-fruit generic competition runs its course and Cytopoint long-acting approval provides a catalyst. International and livestock continue growing at 5–10%. Revenue lands at the midpoint of guidance ($9.82B) in 2026 and returns to 5–6% growth in 2027. EPS recovers from ~$6.93 in 2026 to ~$8.00+ by 2028. At a still-conservative 15× multiple on 2028 estimates, the target is approximately $115–$125 in 18–24 months.

Asymmetry Assessment: Bull case $155 vs. bear case $58 from a $75 entry implies +107% upside vs. −23% downside — a ratio of approximately 4.6:1 in favor of the upside. This is unusually skewed for a wide-moat business with a deep product portfolio and clean management team. The asymmetry reflects the depth of market panic following the Q1 miss rather than a fundamental re-rating. However, the asymmetry is only attractive if you believe the bear case is genuinely unlikely — which requires conviction that U.S. pet healthcare spending is cyclically, not structurally, impaired.